BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24929848)

  • 1. Homing of cytokine-induced killer cells during the treatment of acute promyelocytic leukemia.
    Wang H; Cao F; Li J; Li Y; Liu X; Wang L; Liu Z; Li Y; Zhao H; Zhou J
    Int J Hematol; 2014 Aug; 100(2):165-70. PubMed ID: 24929848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dendritic cell-activated and cytokine-induced killer cell therapy on 22 children with acute myeloid leukemia after chemotherapy.
    Bai Y; Zheng JE; Wang N; Cai HH; Zhai LN; Wu YH; Wang F; Jin RM; Zhou DF
    J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):689-693. PubMed ID: 26489623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery.
    Li H; Wang C; Yu J; Cao S; Wei F; Zhang W; Han Y; Ren XB
    Cytotherapy; 2009; 11(8):1076-83. PubMed ID: 19929470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
    Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
    PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous cytokine-induced killer (CIK) cell immunotherapy combined with cyclophosphamide in five patients with POEMS syndrome.
    Ma L; Wang Y; Bo J; Han W; Wang Y; Zhang L; Wu X; Yu S; Liu R
    Clin Exp Immunol; 2016 Apr; 184(1):83-9. PubMed ID: 26660736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.
    Wang Y; Bo J; Dai HR; Lu XC; Lv HY; Yang B; Wang T; Han WD
    Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC).
    Gu Y; Lv H; Zhao J; Li Q; Mu G; Li J; Wuyang J; Lou G; Wang R; Zhang Y; Huang X
    Int Immunopharmacol; 2017 Sep; 50():263-269. PubMed ID: 28711032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment.
    Liu J; Li H; Cao S; Zhang X; Yu J; Qi J; An X; Yu W; Ren X; Hao X
    J Immunother; 2014; 37(2):115-22. PubMed ID: 24509174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission.
    Linn YC; Yong HX; Niam M; Lim TJ; Chu S; Choong A; Chuah C; Goh YT; Hwang W; Loh Y; Ng HJ; Suck G; Chan M; Koh M
    Cytotherapy; 2012 Aug; 14(7):851-9. PubMed ID: 22799277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells infected by Ad-sh-SOCS1 enhance cytokine-induced killer (CIK) cell immunotherapeutic efficacy in cervical cancer models.
    Zheng Y; Hu B; Xie S; Chen X; Hu Y; Chen W; Li S; Hu B
    Cytotherapy; 2017 May; 19(5):617-628. PubMed ID: 28215653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Researche advances on CIK cells and their clinical use in lung cancer].
    Luo H; Zhou X
    Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):954-9. PubMed ID: 22152697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells.
    Bremm M; Pfeffermann LM; Cappel C; Katzki V; Erben S; Betz S; Quaiser A; Merker M; Bonig H; Schmidt M; Klingebiel T; Bader P; Huenecke S; Rettinger E
    Front Immunol; 2019; 10():1218. PubMed ID: 31214182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion.
    Rettinger E; Kreyenberg H; Merker M; Kuçi S; Willasch A; Bug G; Ullrich E; Wels WS; Bonig H; Klingebiel T; Bader P
    Cytotherapy; 2014 Jun; 16(6):835-44. PubMed ID: 24582456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas.
    Ryu JI; Han MH; Cheong JH; Kim JM; Kim CH
    Immunotherapy; 2017 Mar; 9(5):411-421. PubMed ID: 28357913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of cord blood-derived cytokine-induced killer cells in treatment of patients with malignancies.
    Zhang Z; Wang L; Luo Z; Zhao X; Huang J; Li H; Yang S; Zhao X; Zhang L; Li L; Wang F; Huang L; Zhang Y
    Cytotherapy; 2015 Aug; 17(8):1130-8. PubMed ID: 25963952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polysaccharides from Hedyotis diffusa enhance the antitumor activities of cytokine-induced killer cells.
    Ma C; Wei Y; Liu Q; Xin Y; Cao G; Wang X; Yang P
    Biomed Pharmacother; 2019 Sep; 117():109167. PubMed ID: 31387180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK.
    Wang QJ; Wang H; Pan K; Li YQ; Huang LX; Chen SP; He J; Ke ML; Zhao JJ; Li JJ; Sun JC; Liang XT; Ma HQ; Chen YB; Xia JC
    Chin J Cancer; 2010 Jul; 29(7):641-8. PubMed ID: 20591215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy.
    Helms MW; Prescher JA; Cao YA; Schaffert S; Contag CH
    Cancer Immunol Immunother; 2010 Sep; 59(9):1325-34. PubMed ID: 20532883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.